<DOC>
	<DOCNO>NCT02616354</DOCNO>
	<brief_summary>Explore Imipenem/Cilastatin two-step dosing compare 2 hour infusion patient severe whether obtain good result pharmacokinetic/pharmacodynamic , clinical rational use antimicrobial agent , provide theoretical support optimize dosage regimen .</brief_summary>
	<brief_title>Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin</brief_title>
	<detailed_description>Compared Imipenem/Cilastatin 2 hour continuous dose method two-step dosing method ( 0.5 hour enter half dose , 1.5 hour , half input dose ) blood drug concentration body minimal inhibitory concentration ( MIC ) pathogens percent dose interval duration ( 100 % fT &gt; MIC ) , blood drug concentration body 4 time minimal inhibitory concentration ( MIC ) pathogens percent dose interval duration ( 100 % fT &gt; 4 MIC ) , blood drug concentration peak ratio minimal inhibitory concentration ( MIC ) pathogens ( Cmax/MIC ) , blood drug concentration ( Tmax ) use peak time , use guide clinical patient severe infection Imipenem/Cilastatin usage .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<criteria>sepsis severe sepsis severe infection previous 48 hour treatment imipenem/cilastatin ( recommended hospital microbiologist ) expect duration hospital stay ICU ≥ 72 h recruitment recruit patient agree participate trial , set sign informed consent allergy carbapenems adverse drug reaction imipenem acute chronic renal failure assess serum creatinine concentration &gt; 280 μmol/L ( creatinine clearance &lt; 20mL/min ) require continuous renal replacement therapy drug alcohol abuse Pregnant lactant woman patient near death</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pharmacokinetics ; pharmacodynamic ; imipenem ; sepsis</keyword>
</DOC>